Wellorithm Reviews: The Longevity Line Is Unlisted

The one-sentence version

Wellorithm sells the two things this board is built to rank — a sermorelin injection and an NAD+ injection — and it prices them on the page, which is more than several providers here do. Then it undoes almost all of that: the price carries an asterisk the page never resolves, the four compounded GLP-1 products beside it carry no public figure at all, billing runs every 28 days and is non-refundable once processed, the pharmacy is never named, the site contradicts itself on how many states it serves, and the sermorelin and NAD+ pages are missing from Wellorithm's own navigation and from its own sitemap. It grades C, 4 points out of 14 — tied for the lowest score on this board. The grade is computed from published terms alone and cannot see who pays us.

The finding that nearly cost us the review

We had Wellorithm recorded internally as a provider with no NAD+ and no sermorelin line. That was wrong, and how it got to be wrong is worth publishing, because it is a mistake a reader can make just as easily as we did.

Both product pages are live. `/sermorelin` lists a Sermorelin Injection as "In Stock", and `/nad` lists an NAD+ Injection. Both print prices. Neither is linked from the site's own navigation, and neither appears in its sitemap. Browse Wellorithm the way a customer would and the longevity line does not exist; you have to arrive at those URLs from somewhere else to find it.

Two lessons carried into this review. The first is that a catalogue is what the product pages say, not what the navigation implies. The second is the one we had already been burnt by: Wellorithm's affiliate program lists an "ED (Tadalafil)" payout tier, and Wellorithm does not appear to sell tadalafil at all. A payout tier describes what a vendor could be paid for. It is never evidence of what is on the shelf.

What it is, and who it's for

Wellorithm describes itself in its own Terms as a facilitator, not a practice: "Wellorithm acts as a facilitator, connecting users with licensed healthcare professionals through its Professional Entities. The company itself does not diagnose, treat, or practice medicine." Review is asynchronous, following an online evaluation.

The catalogue splits three ways. The longevity line is a sermorelin injection — "5mL (10mg) vial and homekit included", with "Free expedited shipping", "Compounded in the U.S.A" and "FSA & HSA Eligible" stated on the page — and an NAD+ injection. There is no oral, sublingual or nasal sermorelin route here; the injection is the only way in. The weight-loss line is compounded semaglutide and tirzepatide, each sold as an injection and as an oral dissolving tablet. And there is a branded shelf: Ozempic $1,119/mo, Wegovy $899/mo, Mounjaro $1,399/mo, Zepbound $1,119/mo.

If you want a sermorelin injection and you have found the page, the product is real. If you want to compare it against anything, the rest of this review is the reason that is harder than it should be.

What it actually costs

All figures verified on wellorithm.com on 31 July 2026.

Sermorelin. The price block reads "$150 first month", then "then $200/mo*". A banner promises "Save up to $50 on your first order", "Discount auto-applied at checkout."

The asterisk is not resolved on that page. It is resolved where Wellorithm publishes the same asterisked figure on its NAD+ page, and there it reads: "Price shown applies to 500mg (2.5mL) 3-month plan paid upfront or with buy now, pay later programs. Actual price will depend on product and plan prescribed." Read that sentence twice. It conditions the figure on a three-month plan paid up front, and then says the real number depends on the product and plan prescribed — which is the site telling you, in its own words, that the printed price is not necessarily your price.

NAD+ carries the same structure — "$150 first month", "then $200/mo*" — plus "Only $15/shot*, homekit included" and "Full-strength dosages."

The core weight-loss line has no public price whatsoever. All four compounded semaglutide and tirzepatide SKUs are gated behind Wellorithm's quiz. The branded pens are priced flat — and two of those pages disagree with themselves, which is the next section.

That is the whole case for scoring price transparency at zero. Our rubric asks for a single all-in figure, visible before you commit, that a buyer with no commitment actually pays. Wellorithm's figure is asterisked; the only published resolution of that asterisk attaches a three-month prepay to it and then disclaims itself; and the largest part of the catalogue is not priced at all. Compare the Gala Health review, where an advertised monthly rate turns out to be a yearly one — the failure is the same shape. And compare the System Labs review, which sells the same two injections and prints its standing rate on the same line as its promotional one: publishing the number you keep paying is not a hard thing to do.

The pages disagree with each other

Four separate self-contradictions, all verified on the same day. None of them is a pricing trap on its own; together they are the reason a reader cannot take any single figure on this site at face value.

The sermorelin page carries somebody else's copy. On a page selling a growth-hormone secretagogue, two lines read "NAD+ boosts mitochondrial function to power your day." and "Support DNA repair and longevity enzymes like SIRT1." Those are NAD+ claims, on the sermorelin product page, describing a mechanism sermorelin does not have.

The NAD+ footnote is pasted onto drugs it cannot describe. All four branded-drug pages carry that same "500mg (2.5mL) 3-month plan" NAD+ footnote. Ozempic is not dosed in 500mg vials of NAD+. The footnote is meaningless on those pages and is printed on them anyway.

Two branded pages print two different prices. Ozempic and Zepbound each show $1,119 in the hero and $1,199 in the call to action — on the same page, for the same drug.

The site cannot agree on where it operates. The homepage says "Serving All 50 States"; other pages say 49, excluding Louisiana.

Billing, oversight and the pharmacy

Billing is not monthly, and it is not refundable. Wellorithm's Terms state that "Membership fees are billed every 28 days, and payments are non-refundable once processed." Twenty-eight days is not a month: it is thirteen charges a year, not twelve, against a price advertised as "/mo". And once a charge clears, the Terms say it does not come back. Both facts belong in your arithmetic before the first click, not after.

Oversight scores zero, and the reason is what is missing rather than what is wrong. Review is asynchronous after an online evaluation, and the company's own Terms say it does not practise medicine — it connects you to professional entities that do. What is nowhere stated is whether the clinician visit is included in the $150 or the $200. Our rubric scores an unstated consult exactly as it scores one billed on top, because a buyer cannot budget for a fee nobody has quoted, and we have deliberately left it unresolved rather than assume either way.

Pharmacy scores zero too. "Compounded in the U.S.A" is the entire disclosure. No dispensing facility is named, and no 503A or 503B standard is claimed. FDA's position on what that leaves open is unambiguous: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed¹. For the contrast, Telos Rx prints both of its pharmacies' street addresses and phone numbers.

The evidence behind what it sells

The sermorelin trial record is thin, and Wellorithm's own page does not lean on it — the longevity claims printed there are the NAD+ ones that do not belong on it. The study that tested this protocol gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76: nocturnal growth hormone rose significantly, but IGF-1 did not change, and DEXA-measured muscle and fat did not change². The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events³. See peptides for longevity.

For NAD+, the 2026 PRISMA-guided systematic review screened 113 studies including 33 human intervention trials, found effects on functional, metabolic and vascular outcomes "heterogeneous and often null or endpoint-specific", and reported that no eligible outcomes trial has evaluated injected NAD+ for these indications at all — which is exactly the product Wellorithm sells⁴. See NAD+ for longevity.

One thing genuinely cuts the other way, and it is worth stating on a page this critical. The GLP-1 line Wellorithm will not price is the part of its catalogue with real randomised outcome data behind it: SURMOUNT-1 randomised 2,539 adults with obesity and reported mean weight change at week 72 of −15.0% on 5 mg of tirzepatide, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo⁵. The evidence is on the products with no public price; the prices are on the products with no evidence.

Where it's weak, and who should skip it

Skip it if you are comparing providers on price, because there is no figure here you can compare with confidence. Skip it if the 28-day cycle matters to you — thirteen charges a year against a "/mo" headline is a real difference, and none of them come back. Skip it if you want an oral or nasal sermorelin route, which Wellorithm does not sell. And skip it if the self-contradictions bother you, which they should: a company that prints two prices for Ozempic on one page and NAD+ copy on its sermorelin page is not a company whose fine print you should assume is careful.

If you proceed anyway: get the month-to-month price in writing before you pay, ask explicitly what happens after the first month and whether a three-month prepay is required to hold the rate, ask whether the consultation is included, and confirm you are in a state it actually serves — the site itself gives two different answers.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Wellorithm takes the full four for its longevity line — a sermorelin injection and an NAD+ injection are exactly what this board ranks, and finding them unlisted does not make them unreal. It takes zero everywhere else: zero on price transparency, because the printed figure is asterisked, the only published resolution of that asterisk attaches a three-month prepay and then disclaims itself, and the compounded GLP-1 line carries no public price at all; zero on clinical oversight, because whether the visit is included is never stated; zero on pharmacy, because "Compounded in the U.S.A" names nobody; and zero on human support, which the page does not state is included. Four out of fourteen: a C, tied for the lowest score on this board. The owner of this site has seen that grade and let it stand.

The repairs are unglamorous and entirely within Wellorithm's control: resolve the asterisk on the page it appears on, publish a GLP-1 price, decide whether it serves 49 states or 50, print one price per drug, take the NAD+ copy off the sermorelin page, and put both product pages in the navigation and the sitemap so customers can find them. Do that and the grade moves on merit. Our other C-graded partners are covered in the Gala Health review, the MadeMed review, the Try Ageless review and the Shed review; the full field is at our provider rankings and the scoring is set out in how we grade.